Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, C.
Right arrow Articles by Schor, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, C.
Right arrow Articles by Schor, N. F.
[Cancer Research 62, 4867-4875, September 1, 2002]
© 2002 American Association for Cancer Research


Advances in Brief

TrkA as a Life and Death Receptor

Receptor Dose as a Mediator of Function1

Chaohua Yan, Ye Liang, Karen D. Nylander and Nina Felice Schor2

The Pediatric Center for Neuroscience, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213

Nerve growth factor (NGF) has been implicated as both an inhibitor and an inducer of apoptosis. Binding of NGF to its TrkA receptor is generally considered to have an antiapoptotic effect. However, neuroblastomas that overexpress TrkA have a good prognosis and frequently regress by apoptosis either spontaneously or after chemotherapeutic treatment, whereas those that express little or no TrkA are lethal in 80–95% of patients, despite maximal therapy. We now report that NGF treatment of PC12 neural crest tumor cells trkA-transfected to express TrkA at levels analogous to those seen in "good prognosis" neuroblastomas results in cell death; similar treatment of native cells that express TrkA at levels similar to those of "poor prognosis" neuroblastomas has no effect on cell survival. Morphological and biochemical studies indicate that NGF induces atypical apoptosis that is abrogated by the tyrosine kinase inhibitor K252{alpha}, but not by an inhibitor of NGF-p75 binding, in trkA-transfected PC12 cells. Differential activation of the TrkA-phosphorylated mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase 1-phosphorylated ERK-phosphorylated cAMP-responsive element-binding protein and TrkA-phosphorylated MAP/ERK kinase 3/6-phosphorylated p38 MAP signal transduction pathways, also suppressible by K252{alpha}, occurs in the two cell types. This difference may mediate their differential survival after exposure to NGF.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J.-F. Lavoie, L. LeSauteur, J. Kohn, J. Wong, O. Furtoss, C. J. Thiele, F. D. Miller, and D. R. Kaplan
TrkA Induces Apoptosis of Neuroblastoma Cells and Does So via a p53-dependent Mechanism
J. Biol. Chem., August 12, 2005; 280(32): 29199 - 29207.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.